- Home
- NYC vs LGVN Comparison
NYC vs LGVN Comparison
Compare NYC & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- LGVN
- Stock Information
- Founded
- NYC 2013
- LGVN 2014
- Country
- NYC United States
- LGVN United States
- Employees
- NYC N/A
- LGVN N/A
- Industry
- NYC Real Estate
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NYC Finance
- LGVN Health Care
- Exchange
- NYC Nasdaq
- LGVN Nasdaq
- Market Cap
- NYC 27.6M
- LGVN 27.6M
- IPO Year
- NYC N/A
- LGVN 2021
- Fundamental
- Price
- NYC $11.33
- LGVN $1.61
- Analyst Decision
- NYC
- LGVN Strong Buy
- Analyst Count
- NYC 0
- LGVN 3
- Target Price
- NYC N/A
- LGVN $8.67
- AVG Volume (30 Days)
- NYC 9.2K
- LGVN 118.8K
- Earning Date
- NYC 05-09-2025
- LGVN 05-13-2025
- Dividend Yield
- NYC N/A
- LGVN N/A
- EPS Growth
- NYC N/A
- LGVN N/A
- EPS
- NYC N/A
- LGVN N/A
- Revenue
- NYC $61,570,000.00
- LGVN $2,392,000.00
- Revenue This Year
- NYC $8.40
- LGVN $1.30
- Revenue Next Year
- NYC $1.62
- LGVN $19.15
- P/E Ratio
- NYC N/A
- LGVN N/A
- Revenue Growth
- NYC N/A
- LGVN 237.38
- 52 Week Low
- NYC $5.46
- LGVN $0.77
- 52 Week High
- NYC $13.59
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- NYC 51.31
- LGVN 55.99
- Support Level
- NYC $11.13
- LGVN $1.45
- Resistance Level
- NYC $11.70
- LGVN $1.46
- Average True Range (ATR)
- NYC 0.98
- LGVN 0.14
- MACD
- NYC -0.05
- LGVN 0.02
- Stochastic Oscillator
- NYC 45.72
- LGVN 100.00
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.